INTRODUCTION
============

Ataxias are a heterogeneous group of neurological disorders characterized by loss of coordination due to alteration of cerebellar functions. Friedreich's ataxia (FRDA) is the most prevalent hereditary ataxia in Caucasians. FRDA is characterized by progressive spinocerebellar and sensory ataxia with absence of deep tendon reflexes, dysarthria, pyramidal signs, muscular weakness and positive extensor plantar responses ([@b15-0050860]; [@b28-0050860]). Neurological symptoms result from degeneration of large sensory neurons in the dorsal root ganglia (DRG) and posterior columns in the spinal cord, followed by degeneration of the spinocerebellar and corticospinal tracts and of the dentate nucleus. FRDA is also characterized by primary non-neurological manifestations including hypertrophic cardiomyopathy and increased incidence of diabetes ([@b16-0050860]). The mutated gene in FRDA encodes a small protein called frataxin ([@b7-0050860]; [@b6-0050860]). All FRDA patients carry at least one expansion of a GAA triplet repeat in the first intron of the *FXN* gene. Most patients are homozygous for this mutation, but a few patients (4%) are compound heterozygous for the GAA expansion and a different mutation (nonsense, missense, deletions, insertions) leading to loss of frataxin function ([@b6-0050860]; [@b8-0050860]; [@b14-0050860]). The presence of the GAA expansion leads to transcriptional silencing of *FXN*, resulting in diminished (but not absent) residual expression of a structurally and functionally normal frataxin protein in patients. The pathophysiology of FRDA in patients is characterized by intracellular iron deposits ([@b20-0050860]) and a deficit in mitochondrial iron-sulfur (Fe-S) cluster-containing enzymes (aconitase and respiratory chain complexes I--III) ([@b34-0050860]). The presence of markers of oxidative damage in blood and urine samples of individuals with FRDA has also been reported ([@b4-0050860]; [@b12-0050860]; [@b37-0050860]), but the correlation between these markers and disease features is complicated ([@b10-0050860]; [@b27-0050860]; [@b38-0050860]).

Frataxin is a small evolutionary conserved protein and is located in mitochondria in eukaryotes ([@b7-0050860]; [@b35-0050860]). Although the exact function of frataxin is still unclear, there is now clear evidence that frataxin is involved in Fe-S cluster biogenesis through its binding to the core complex of the mitochondrial de novo Fe-S cluster machinery ([@b36-0050860]; [@b44-0050860]).

###### TRANSLATIONAL IMPACT

**Clinical issue**

Friedreich's ataxia (FRDA) is the most common hereditary ataxia, affecting 1 in 50,000 individuals in the Caucasian population. FRDA is characterized by a mixed sensory and spinocerebellar ataxia, primarily resulting from the degeneration of sensory neurons in the dorsal root ganglia, and by primary non-neurological manifestations, including hypertrophic cardiomyopathy and glucose intolerance. The disease-causing gene encodes frataxin, a small mitochondrial protein involved in the biogenesis of iron-sulfur clusters, which are vital cellular cofactors. FRDA is caused by an intronic GAA repeat expansion mutation that is present on both alleles in most patients, leading to a drastic decrease of frataxin expression. In the past 10 years, the development of mouse models of FRDA using conditional approaches or GAA-based strategies has advanced our understanding of FRDA genetics and pathophysiology, and of the cellular function of frataxin. Interestingly, the characterization of a liver-specific conditional mouse model (obtained through deletion of the frataxin gene using the albumin-promoter-driven Cre recombinase) showed that frataxin deficiency caused liver tumorigenesis, suggesting that frataxin is a tumor suppressor protein. Combining these results with rare case reports of neoplasia in individuals with FRDA led to the hypothesis that individuals with FRDA might be predisposed to cancer.

**Results**

This paper combines the clinical investigations on cancer reports carried out on the largest cohorts of individuals with FRDA from the United States, Australia and Europe with a new, more detailed characterization of the liver conditional mouse model. The clinical investigations demonstrate that cancer is not a common finding in individuals with FRDA, and that the incidence of cancer is no higher than in the general population. In addition, a reexamination of the liver conditional mouse model demonstrates that frataxin deficiency triggers early mitochondrial dysfunction, iron-sulfur cluster deficits and cell death, leading to reduced life span in most of the mice. Abnormal peripheral structures, similar to those previously associated with tumor formation, were observed only in a minority of mice with normal life expectancy and were shown to be mainly composed of dying, frataxin-deficient cells, rather than proliferating tumor cells. The majority of the liver in these surviving mice is composed of functional hepatocytes, owing to incomplete deletion of the frataxin gene; these provide a pool of cells for liver regeneration.

**Implications and future directions**

The data demonstrate that FRDA is not associated with cancer predisposition, unlike other neurodegenerative disorders such as ataxia telangiectasia, a distinct recessive ataxia. The absence of cancer predisposition in FRDA is important for the clinical management of patients and for developing appropriate therapeutic approaches. Furthermore, these findings provide evidence that frataxin is unlikely to be a tumor suppressor and that tumor formation in frataxin-deficient liver was previously reported owing to misinterpretation of an artifact. Although accurate characterization of the liver phenotype underlying frataxin deficiency can be carried out in young mice, these results also illustrate the limitations of the albumin-promoter-driven Cre recombinase system for generating liver-specific conditional mouse models.

To characterize and understand the molecular and genetic basis of FRDA, conditional knockout mice ([@b31-0050860]; [@b33-0050860]; [@b39-0050860]; [@b41-0050860]) and GAA-based mouse models with partial deficiency of frataxin ([@b2-0050860]; [@b25-0050860]) were generated. Cardiac and neurological conditional mouse models ([@b31-0050860]; [@b39-0050860]), as well as mice expressing the human *FXN* locus containing an expanded GAA repeat ([@b2-0050860]), reproduce clinical and biochemical features observed in FRDA patients, including hypertrophic cardiomyopathy, a mixed sensory and spinocerebellar ataxia, Fe-S cluster enzyme deficit and mitochondrial iron accumulation.

Among the mouse models of FRDA, the conditional *Fxn* deletion in liver was reported to trigger tumorigenesis ([@b42-0050860]; [@b43-0050860]; [@b41-0050860]), suggesting that frataxin is a tumor suppressor protein and that FRDA might be associated with a predisposition to cancer. At the molecular level, tumorigenesis in frataxin-deficient cells was proposed to be the result of higher cellular sensitivity to oxidative stress and impaired capacity of the cellular DNA repair machinery ([@b42-0050860]; [@b41-0050860]). Interestingly, Ataxia telangiectasia (AT), a distinct early-onset autosomal recessive ataxia due to mutations in the *ATM* gene, is biochemically associated with susceptibility to reactive oxygen species and DNA repair defects, and is clinically associated with predisposition to neoplasia ([@b29-0050860]). To date, no clinical investigation regarding the correlation between FRDA and cancer has ever been pursued, and only rare case reports, which cannot conclusively establish a link between frataxin deficiency and neoplasia in human, are available in the literature ([@b1-0050860]; [@b3-0050860]; [@b9-0050860]; [@b18-0050860]; [@b26-0050860]).

In the present study, we used natural history data from clinical studies based on the largest cohorts of FRDA patients from the USA, Australia and Europe to investigate predisposition to neoplasia. As no overrepresentation of cancer in individuals with FRDA was observed, we, in parallel, revisited the characterization of the liver-specific conditional mouse model in which the suggestion of a link with tumorigenesis was reported. Our results demonstrate that *Fxn* deletion in liver triggers early mitochondriopathy, with the classic hallmarks of frataxin deficiency. Only a minority of mice developed abnormal liver structures similar to those previously associated with tumor formation. However, the peripheral abnormal structures were composed mainly of dying, frataxin-deficient hepatocytes whereas the inner liver structure in these mice contained proliferating frataxin-positive hepatocytes that contributed to liver regeneration, increased survival and an increase in body weight. The tumor-like lobules therefore appeared to be degenerating liver masses rather than composed by proliferating cancer cells, as previously suggested by Thierbach and colleagues ([@b42-0050860]; [@b43-0050860]; [@b41-0050860]). Together, our data demonstrate that an association between frataxin deficiency and tumorigenesis should be reconsidered.

RESULTS
=======

Clinical investigations show no higher occurrence of cancer in FRDA patients
----------------------------------------------------------------------------

To determine the incidence of cancer in individuals with FRDA, we took advantage of ongoing natural history studies based on cohorts from the USA and Australia (FA-COMS cohort), and from Europe (EFACTS cohort). The FA-COMS cohort (*n*=578) was 50% female with a mean age of 28.1 years (range 7--78). Mean length of the shorter GAA allele was 608 repeats, with 18 people carrying point mutations in conjunction with a single expanded allele. Mean age of onset was 13.8 years. Interim neurologic results from this cohort have previously appeared ([@b13-0050860]), although none has reported aspects of neoplasia. There were a total of 1694 visits (1115 follow-up visits), including several subjects up to 8 years after the initial visit. The annual follow-up rate at year 1 is 65%, and is largely maintained after that time. Eight neoplasms were identified in seven of the 578 subjects with FRDA ([Table 1](#t1-0050860){ref-type="table"}). These included four dermatologic cancers (two melanomas and two basal cell carcinomas), two breast cancers, one chronic lymphocytic leukemia and one osteosarcoma ([Table 1](#t1-0050860){ref-type="table"}). Excluding the basal cell cancers that are not tracked in the general population statistics, the prevalence of cancer in the FA-COMS cohort was of 1.04% (6/578). Four patients were diagnosed with cancer before their initial study participation, while the remaining cancers were captured during study participation with an incidence of approximately one cancer per 250 patient-years (0.4% per year). Only one patient, with breast cancer, was deceased from the cancer. The EFACTS cohort (with currently 361 patients) was 53.2% females with a mean age of 34.6 (range 7--76). To date, only baseline data are available for this cohort because no follow-up visits have yet started. Molecular diagnosis for FRDA was confirmed in all individuals. Neoplasm was identified in 12 of the 361 individuals with FRDA ([Table 2](#t2-0050860){ref-type="table"}), but only five of them developed cancer: three subjects were diagnosed for breast cancer, one for thyroid carcinoma and one for melanoma ([Table 2](#t2-0050860){ref-type="table"}), therefore giving a prevalence of cancer of 1.38% (5/361).
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Clinical investigation of neoplasms in the FA-COMS cohort (*n* = 578)

![](DMM009829T1)

###### 

Clinical investigation of neoplasms in the EFACTS cohort (*n*=361)

![](DMM009829T2)

Together, data obtained with FA-COMS and EFACTS cohorts showed that cancer is not a common finding in the medical history of individuals with FRDA. Furthermore, no high incidence of cancer could be detected after several years of follow-up in the FA-COMS cohort.

Liver-specific deletion of *Fxn* in mouse triggers early mitochondriopathy
--------------------------------------------------------------------------

The idea that frataxin might be a tumor suppressor is essentially based on the evidence of tumor-like structure formation in a mouse model in which *Fxn* was specifically deleted in liver (*Alb-Cre-Fxn^L3/L−^* mice) ([@b42-0050860]; [@b43-0050860]; [@b41-0050860]). To confirm whether frataxin depletion triggers tumorigenesis in mouse liver, we raised a new generation of liver-specific conditional mice. These mice were obtained as previously described by Thierbach and colleagues ([@b41-0050860]), using the same mouse strain carrying the conditional allele that was created in our laboratory (allowing deletion of exon 4 of *Fxn*) ([@b31-0050860]), as well as the same mouse strain carrying an *albumin* promoter-driven *Cre* transgene ([@b30-0050860]).

The newly generated *Alb-Cre-Fxn^L3/L−^* mice were born in the expected Mendelian ratio (data not shown). Drastic frataxin depletion in the liver was observed at 2 weeks of age by western blot ([Fig. 1A](#f1-0050860){ref-type="fig"}). Both female and male *Alb-Cre-Fxn^L3/L−^* mice had a normal body weight at birth ([Fig. 1B](#f1-0050860){ref-type="fig"} and data not shown), but, starting from 4 weeks on, female and male *Alb-Cre-Fxn^L3/L−^* mice failed to gain weight ([Fig. 1B](#f1-0050860){ref-type="fig"} and data not shown). Life expectancy was also significantly decreased in *Alb-Cre-Fxn^L3/L−^* mice; 50% died before 8 weeks of age ([Fig. 1C](#f1-0050860){ref-type="fig"}). However, approximately 20% of *Alb-Cre-Fxn^L3/L−^* mice showed a normal life expectancy compared with control mice ([Fig. 1C](#f1-0050860){ref-type="fig"}). Interestingly, these surviving *Alb-Cre-Fxn^L3/L−^* mice (*Alb-Cre-Fxn^L3/L--(S)^*) went through the same incapacity to thrive as the majority of *Alb-Cre-Fxn^L3/L−^* mice ([Fig. 1B](#f1-0050860){ref-type="fig"}), but then progressively gained weight with age to finally reach levels similar to control levels ([Fig. 1B](#f1-0050860){ref-type="fig"}). This phenomenon was observed in both males and females, indicating the absence of a gender bias (data not shown).

![**Conditional deletion of *Fxn* gene in the liver.** A) Representative western blot showing frataxin expression level in liver samples from 2-week-old control and *Alb-Cre-Fxn^L3/L−^* mice. (B) Weight curves obtained with control (*n*=12), *Alb-Cre-Fxn^L3/L−^* with reduced life expectancy (*n*=10) and surviving *Alb-Cre-Fxn^L3/L−^* (*Alb-Cre-Fxn^L3/L--(S)^*, *n*=2) females. Values are shown as the average obtained for each age ± s.d. (C) Survival curves obtained with control (*n*=16) and *Alb-Cre-Fxn^L3/L−^* (*n*=23) mice. (D,E) Photographs of control mouse liver (D) and *Alb-Cre-Fxn^L3/L−^* mouse liver with strong lipid accumulation (E) at 4 weeks. (F,G) H&E staining of liver sections from control (F) and *Alb-Cre-Fxn^L3/L−^* (G) mice at 4 weeks. (H,I) Oil Red staining of liver sections from control (H) and *Alb-Cre-Fxn^L3/L−^* (I) mice. (J) Ultrastructural analysis of *Alb-Cre-Fxn^L3/L−^* liver at 4 weeks by electron microscopy. m, mitochondria; L, lipid droplets; N, nucleus. Scale bar: 2 μm.](DMM009829F1){#f1-0050860}

To understand the early consequences of frataxin depletion in liver, mice were dissected at 4 weeks after birth. Macroscopically, steatosis was a constant feature of the liver of *Alb-Cre-Fxn^L3/L−^* mice ([Fig. 1D](#f1-0050860){ref-type="fig"},E), although the level of lipid accumulation varied between mice (data not shown). On hematoxylin-eosin (H&E) stained sections, the structure of the liver was affected in *Alb-Cre-Fxn^L3/L−^* mice as compared with control, with larger hepatocytes and the presence of vacuoles characteristic of lipid accumulation ([Fig. 1F,G](#f1-0050860){ref-type="fig"}). Steatosis was confirmed by Oil Red staining ([Fig. 1H,I](#f1-0050860){ref-type="fig"}). Ultrastructural analysis by electron microscopy showed highly affected hepatocytes in *Alb-Cre-Fxn^L3/L−^* mice compared with control ([Fig. 1J](#f1-0050860){ref-type="fig"} and [supplementary material Fig. S1A--C](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)), with the presence of giant mitochondria and abnormal mitochondrial structures showing loss of matrix material and loss of cristae ([Fig. 1J](#f1-0050860){ref-type="fig"} and [supplementary material Fig. S1C](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). Lipid droplets were also observed ([Fig. 1J](#f1-0050860){ref-type="fig"}). The nuclear structure displayed necrotic features in most hepatocytes ([Fig. 1J](#f1-0050860){ref-type="fig"} and [supplementary material Fig. S1C](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). In a few of the affected mitochondria, electron-dense deposits were observed ([supplementary material Fig. S1D,E](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). These aggregates are reminiscent of the characteristic iron deposits identified in patients ([@b19-0050860]; [@b23-0050860]) and in the cardiac mouse model of FRDA ([@b31-0050860]). Together, the results show that the early phenotype is characterized by highly affected hepatocytes with mitochondrial dysfunction and rare but significant electron-dense intramitochondrial deposits, classic hallmarks of frataxin-deficient tissues and cells ([@b5-0050860]; [@b23-0050860]; [@b31-0050860]). Furthermore, mitochondrial dysfunction in *Alb-Cre-Fxn^L3/L−^* mice is associated with liver steatosis.

Lobule structures composed of abnormal hepatocytes progressively form on the liver surface of surviving *Alb-Cre-Fxn^L3/L--(S)^* mice
-------------------------------------------------------------------------------------------------------------------------------------

The evolution of the liver phenotype with age was analyzed by dissecting the surviving *Alb-Cre-Fxn^L3/L--(S)^* mice at 15, 20 and 30 weeks. At dissection, livers of *Alb-Cre-Fxn^L3/L--(S)^* mice were significantly smaller in size ([Fig. 2A](#f2-0050860){ref-type="fig"} and [supplementary material Fig. S2A](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)), with occasionally one or more lobes of the liver absent (data not shown). Furthermore, progressive formation of abnormal structures on the surface of the liver of *Alb-Cre-Fxn^L3/L--(S)^* mice was observed ([Fig. 2A](#f2-0050860){ref-type="fig"} and [supplementary material Fig. S2A](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). These structures strongly resemble the lobules described by Thierbach and colleagues ([@b42-0050860]; [@b41-0050860]) that were identified as tumors. No steatosis was observed at these ages, both macroscopically ([Fig. 2A](#f2-0050860){ref-type="fig"}) and by Oil Red staining of liver sections (data not shown). H&E stained sections of the lobules revealed that these structures were essentially composed of large cells surrounded by areas of fibrosis ([Fig. 2B](#f2-0050860){ref-type="fig"} and [supplementary material Fig. S2B,C](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). Ultrastructural analysis of the lobules showed that the large cells were hepatocytes containing highly proliferating abnormal mitochondria ([Fig. 2C--E](#f2-0050860){ref-type="fig"}) with clear matrix and electron-dense deposits ([Fig. 2E](#f2-0050860){ref-type="fig"}), the presence of cellular debris, and that some cells had clear features of dying cells ([Fig. 2D](#f2-0050860){ref-type="fig"}), thus suggesting that these cells are frataxin-deficient. Large abnormal cells were, however, observed only on the periphery of the liver of *Alb-Cre-Fxn^L3/L--(S)^* mice within the lobules ([supplementary material Fig. 2C](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). Indeed, H&E stained sections of the inner structure of liver from *Alb-Cre-Fxn^L3/L--(S)^* mice revealed a normal liver organization, with hepatocytes displaying normal features as compared with control mice ([Fig. 2F,G](#f2-0050860){ref-type="fig"} and [supplementary material Fig. 2C](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)).

![**Evolution of the liver structure from 15 weeks to 30 weeks.** (A) Photographs of livers from control and *Alb-Cre-Fxn^L3/L−^* mice at 15, 20 and 30 weeks. (B) H&E staining of a lobule of a 20-week-old *Alb-Cre-Fxn^L3/L−^* mouse. (C-E) Ultrastructural analysis of hepatocytes within a lobule of a 20-week-old *Alb-Cre-Fxn^L3/L−^* mouse. (F) H&E staining of the liver of a 20-week-old control mouse. (G) H&E staining of the inner structure of a liver in a 20-week-old *Alb-Cre-Fxn^L3/L−^* mouse. Scale bars: 5 μm (C,D) and 1 μm (E). Arrow, dense intramitochondrial iron deposit; f, fibrosis; m, mitochondria; star, cellular debris; N, nucleus; m/m, dividing mitochondria.](DMM009829F2){#f2-0050860}

Lobule formation and mouse survival correlate with frataxin re-expression in liver
----------------------------------------------------------------------------------

Frataxin is involved in the early steps of Fe-S cluster biogenesis ([@b36-0050860]; [@b44-0050860]), and its depletion in mouse tissue leads to Fe-S cluster deficit ([@b22-0050860]; [@b31-0050860]; [@b41-0050860]). We therefore investigated the impact of *Fxn* deletion on Fe-S cluster-dependent enzymes in the liver of *Alb-Cre-Fxn^L3/L−^* mice at different ages. Succinate dehydrogenase (SDH) activity was previously reported to be strongly affected in *Alb-Cre-Fxn^L3/L−^* mice ([@b41-0050860]). Using SDH-staining of liver cryosections, we confirmed a strong deficit of SDH activity at 4 weeks ([Fig. 3A,B](#f3-0050860){ref-type="fig"}). However, whereas a deficit was also observed in the lobules of 20-week-old surviving mice ([Fig. 3C](#f3-0050860){ref-type="fig"}), the inner liver structure of *Alb-Cre-Fxn^L3/L--(S)^* mice at 20 weeks displayed normal SDH activity ([Fig. 3D](#f3-0050860){ref-type="fig"}). Glutamine phosphoribosylpyrophosphate amidotransferase (GPAT) maturation and xanthine oxidoreductase (XOR) activity, both dependent on Fe-S cluster biogenesis, were also previously reported to be affected in frataxin-deficient mouse livers at 4 weeks ([@b22-0050860]). GPAT maturation was confirmed to be impaired at 4 weeks in *Alb-Cre-Fxn^L3/L−^* mice by western blot ([Fig. 3E](#f3-0050860){ref-type="fig"}). Whereas the maturation was still impaired at 15 weeks ([Fig. 3E](#f3-0050860){ref-type="fig"}), the protein level of the mature form of GPAT (matGPAT) was back to normal at 20 and 30 weeks ([Fig. 3E](#f3-0050860){ref-type="fig"}). Similarly, XOR activity in liver of *Alb-Cre-Fxn^L3/L−^* mice progressively increased with age and no difference could be observed between *Alb-Cre-Fxn^L3/L--(S)^* and control mice at 30 weeks ([Fig. 3F](#f3-0050860){ref-type="fig"}). Interestingly, the increase in Fe-S cluster-dependent activities correlated with the progressive increase of frataxin expression in the liver of *Alb-Cre-Fxn^L3/L−^* mice, as determined by western blot ([Fig. 3E](#f3-0050860){ref-type="fig"}) and quantitative real-time PCR (qRT-PCR) ([Fig. 3G](#f3-0050860){ref-type="fig"}).

![**Re-expression of frataxin in surviving *Alb-Cre-Fxn^L3/L−^* mice.** (A--D) Succinate dehydrogenase staining of liver sections from control (A) and *Alb-Cre-Fxn^L3/L−^* (B) mice at 4 weeks, and of a lobule (C) or the inner liver structure (D) at 20 weeks. (E) Western blot on liver extracts from 4-, 15-, 20- and 30-week-old control (ct) and *Alb-Cre-Fxn^L3/L−^* (mt) mice using specific antibodies against GPAT, GAPDH and frataxin. matGPAT, mature form of GPAT; \*, non-specific band. (F) In-gel xanthine oxido-reductase activity using liver extracts from 4-, 20- and 30-week-old control (ct) and *Alb-Cre-Fxn^L3/L−^* (mt) mice. (G) Frataxin mRNA levels in liver from mice aged 4 weeks (*n*=3) and 30 weeks (*n*=3) as determined by qRT-PCR. Values are given as the mean ± s.d. NS, not significant.](DMM009829F3){#f3-0050860}

Older surviving mice show liver regeneration
--------------------------------------------

To determine the reason for the expression of frataxin in older surviving *Alb-Cre-Fxn^L3/L--(S)^* mice, genotyping was performed on liver samples of 4- and 30-week-old mice. The *Fxn^L3^* conditional allele that was used to generate the *Alb-Cre-Fxn^L3/L−^* mice contains three *LoxP* sites ([@b31-0050860]): two sites surrounding the Neomycin-resistant cassette (*LoxP\#1* and *LoxP\#2*), and a third site (*LoxP\#3*) bracketing with *LoxP\#2* exon 4 of *Fxn* ([supplementary material Fig. S3A](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). When the Cre recombinase is expressed, three recombination events are possible: the most efficient recombination occurs between *LoxP\#1* and *LoxP\#3*, therefore leading to the *Fxn^L−^* allele ([supplementary material Fig. S3A](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)); recombination between *LoxP\#1* and *LoxP\#2*, or between *LoxP\#2* and *LoxP\#3* can also occur to give the *Fxn^L2+^* or *Fxn^L2−^* allele, respectively. Whereas the *Fxn^L2−^* allele leads to the absence of frataxin expression, the *Fxn^L2+^* allele allows normal frataxin expression. However, if the Cre recombinase expression is maintained, the *Fxn^L2+^* allele can undergo further recombination to give rise to the *Fxn^L−^* allele ([supplementary material Fig. S3A](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). However, data from our laboratory suggest that this recombination is less efficient than recombination between *LoxP\#1* and *LoxP\#3* of the *Fxn^L3^* allele (H.P. and L.R., unpublished data).

At 4 weeks, genotyping of liver of *Alb-Cre-Fxn^L3/L−^* mice revealed the presence of the Cre recombinase (as expected from tail genotyping), the presence of the *Fxn^L^*^−^ allele and a signal for the *Fxn^L3^* allele that is most likely due to the presence of hepatic cells that do not express albumin (Kupffer cells and endothelial cells) ([Fig. 4A](#f4-0050860){ref-type="fig"}). Interestingly, at 30 weeks, genotyping of *Alb-Cre-Fxn^L3/L−^* mice showed the additional presence of a PCR product longer than the product obtained for the wild-type (+) allele ([Fig. 4A](#f4-0050860){ref-type="fig"}). This product corresponds to the *Fxn^L2+^* allele, as confirmed by DNA sequencing ([supplementary material Fig. S3B](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)), thus demonstrating that a significant subset of hepatocytes had only partially recombined and retained exon 4. In addition, quantitative evaluation of the complete deletion of *Fxn^L3^* allele in liver using qRT-PCR on genomic DNA showed an underrepresentation of the *Fxn^L−^* allele in *Alb-Cre-Fxn^L3/L−^* mice at 30 weeks compared with 4 weeks ([Fig. 4B](#f4-0050860){ref-type="fig"}), indicating that liver is composed of a mixed population of deleted and undeleted hepatocytes at 30 weeks.

![**Phenotype of surviving *Alb-Cre-Fxn^L3/L−^* mice is due to liver regeneration.** (A) Genotyping using liver samples from control (*Alb-Cre-Fxn^+/L3^*) and *Alb-Cre-Fxn^L3/L−^* mice at 4 and 30 weeks as indicated. (B) Quantitative evaluation of L-allele copy number in the liver of two controls (*Alb-Cre-Fxn^+/L3^*), two *Alb-Cre-Fxn^L3/L−^* mice at 4 weeks and two *Alb-Cre-Fxn^L3/L−^* mice at 30 weeks by RT-PCR. Values are given as the mean of triplicates for each mouse ± s.d. (C) Albumin mRNA level in liver from mice aged 4 weeks (*n*=3) and 30 weeks (*n*=3) as determined by qRT-PCR. Values are given as the mean ± s.d. (D) *Ki67* expression as observed using immunohistochemistry on liver sections of 20-week-old control and *Alb-Cre-Fxn^L3/L−^* mice.](DMM009829F4){#f4-0050860}

To assess the impact of frataxin re-expression on liver function, we measured the capacity of liver to synthesized albumin, a capacity that has been previously shown to be impaired in *Alb-Cre-Fxn^L3/L−^* mice due to liver failure ([@b41-0050860]). Whereas the level of mRNA encoding albumin was drastically decreased at 4 weeks ([Fig. 4C](#f4-0050860){ref-type="fig"}), the mRNA levels were similar between surviving *Alb-Cre-Fxn^L3/L--(S)^* and control mice at 30 weeks ([Fig. 4C](#f4-0050860){ref-type="fig"}), thus indicating that the liver is functional at 30 weeks.

Liver is an organ that can regenerate in the context of massive hepatocyte death and liver mass loss (for a review see [@b24-0050860]). Because liver mass loss was clearly observed during dissection of the surviving *Alb-Cre-Fxn^L3/L--(S)^* mice ([Fig. 2A](#f2-0050860){ref-type="fig"} and [supplementary material Fig. S2A](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)), we wondered whether the undeleted hepatocytes identified by genotyping could form a pool of cells for liver regeneration. To address this question, we assessed the capacity of hepatocytes to proliferate by immunohistochemistry using *Ki67* expression as a marker ([Fig. 4D](#f4-0050860){ref-type="fig"}). Whereas no signal was observed in control mice ([Fig. 4D](#f4-0050860){ref-type="fig"}), the liver of *Alb-Cre-Fxn^L3/L--(S)^* mice displayed numerous nuclei positive for KI67 at 20 weeks ([Fig. 4D](#f4-0050860){ref-type="fig"}). From the different sections that were analyzed, only hepatocytes displaying a normal morphology were positive for KI67, and no signal was observed in the large hepatocytes constituting the lobules (data not shown).

Together, the data indicate that older surviving *Alb-Cre-Fxn^L3/L--(S)^* mice can survive due to liver regeneration from undeleted hepatocytes that gives rise to a mainly functional organ.

DISCUSSION
==========

The present work shows that cancer is not a common finding in the medical history of persons with FRDA. The prevalence determined for the FA-COMS is 1.04% and is clearly below the 3.39% that corresponds to the 19-year prevalence of cancer determined for the general US population (<http://seer.cancer.gov/faststats>) ([supplementary material Table S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). Similarly, in 2008, a 5-year prevalence in the adult population of western Europe was reported to be 1.89% (GLOBOCAN 2008, <http://globocan.iarc.fr>). If only adults (\>20 years) are considered, the EFACTS cohort shows a prevalence of 1.64% (5/304), a value also below the prevalence of cancer for the European population ([supplementary material Table S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). The difference between the general population and our cohorts can essentially be explained by the difference in age distribution and the lower mean age of the FRDA cohorts ([supplementary material Table S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). It is also worth noting that in both FRDA cohorts, the mean age at cancer diagnosis was over 40 years ([supplementary material Table S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)), suggesting that, as for the general population, cancer is associated with aging rather than with FRDA. Furthermore, the observed incidence of cancer in the FA-COMS study was less than 0.48% per year, the incidence observed in the US population ([supplementary material Table S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)). In addition, the neoplasms observed in individuals with FRDA were not typically highly aggressive and were not clustered in any subtype.

Although FRDA shares some of the biochemical features with ataxia telangiectasia (AT), in particular sensitivity to oxidative stress, it does not share the clinical predisposition for tumor susceptibility. Ataxia with oculomotor apraxia type 1, another recessive ataxia, shares the biochemical features of susceptibility to DNA damage with AT (for a review, see [@b32-0050860]), but also has no clear increased risk of neoplasia ([@b21-0050860]). Therefore, the clinical data provided herein further suggest that only AT among recessive ataxias is conclusively linked to tumorigenesis.

Our clinical study might be limited by two confounders. The first is that individuals with both FRDA and cancer might be less likely to participate in a natural history study such as those analyzed here. The second is that existing patients who develop serious cancers might be lost to follow-up, and thus the cancer might not be recorded in their updated medical history. Still, the number of identified cases of cancer in our study is so low that it is unlikely that these confounders would fundamentally obscure a susceptibility to tumors in FRDA. Furthermore, previous clinical reports match the findings observed in the natural history cohorts. Cancer was not a major cause of death in a recent study of mortality in FRDA ([@b45-0050860]), and previous reports of neoplasms in FRDA have mainly been case reports of distinct uncommon tumors with single subjects ([@b3-0050860]; [@b9-0050860]; [@b26-0050860]), or multiple (two) cases of distinct neoplasms in siblings with FRDA ([@b1-0050860]). Such associations are most readily explained by coincidence or the presence of non-frataxin-related genetic susceptibility such as in the case report of two sisters with FRDA presenting breast cancer ([@b18-0050860]). Thus, although we cannot prove that FRDA has no association with cancer, particularly for rare forms of cancer, the clinical data presented here and published elsewhere ([@b45-0050860]) do not support such an association. Furthermore, it is worth pointing out that, in particular, no liver cancer was detected in the natural history of the cohorts analyzed herein, despite reports of tumors in the liver conditional mouse model ([@b42-0050860]; [@b43-0050860]; [@b41-0050860]).

To understand how frataxin deficiency could trigger apparent tumorigenesis in liver, we generated a new colony of *Alb-Cre-Fxn^L3/L−^* mice using the same strategy in a predominantly C57BL/6J genetic background (\>80%), as previously described ([@b41-0050860]). The general characteristics of the new generation of *Alb-Cre-Fxn^L3/L−^* mice were similar to those previously reported, if we take into account the fact that weight curves were previously described up to 10 weeks of age and life expectancy was only recorded from 5 weeks of age on ([@b41-0050860]). The partial description of survival and weight evolution in *Alb-Cre-Fxn^L3/L−^* mice made by Thierbach and colleagues prevented two important observations: first, that only 20% of *Alb-Cre-Fxn^L3/L−^* mice (and not 50% as previously reported) show normal life expectancy; and second, that the *Alb-Cre-Fxn^L3/L−^* mice that did not show reduced life span progressively gained weight after 10 weeks of age to finally reach levels similar to those of control mice. Furthermore, we showed that only the surviving *Alb-Cre-Fxn^L3/L--(S)^* mice displayed the progressive formation of abnormal structures on the liver structure, i.e. lobules that were previously identified as tumors ([@b41-0050860]). In this context, two main questions had to be addressed: Why do the majority of *Alb-Cre-Fxn^L3/L−^* mice die before 8 weeks? And, more provocatively, how would tumor formation lead to survival in older *Alb-Cre-Fxn^L3/L−^* mice?

By characterizing the *Alb-Cre-Fxn^L3/L−^* mice at 4 weeks of age, we observed a strongly affected liver, displaying the classic hallmarks of frataxin-deficient tissue such as abnormal mitochondrial structures, deficit of Fe-S cluster-dependent activities and intramitochondrial electron-dense deposits reminiscent of iron deposits. The strong liver failure that was observed at this age is the most likely reason for the incapacity to thrive and the early death of *Alb-Cre-Fxn^L3/L−^* mice. Interestingly, it was recently reported that FRDA patients display subclinical mitochondrial dysfunction in the liver ([@b40-0050860]).

The formation of lobule structures previously associated with tumor formation could only be observed in later stages, mainly between 20 and 30 weeks of age. These lobules contained large hepatocytes displaying key features of frataxin-deficient cells: mitochondrial dysfunction (deficient SDH activity, mitochondrial proliferation, clear matrix and loss of cristae), intramitochondrial electron-dense deposits and signs of cell death. However, a normal inner liver structure was observed in *Alb-Cre-Fxn^L3/L--(S)^* mice at 20 and 30 weeks and correlated with the increase in Fe-S cluster-dependent activities, increased level of frataxin expression and a normal liver function. Genotyping of liver samples further demonstrated that frataxin re-expression was due to the presence of hepatocytes with partially recombined *Fxn^L2+^* allele. Together with clear evidence of liver mass loss and cellular proliferation, these results suggest that the phenotype leading to normal liver function, gain of weight and survival involves liver regeneration through proliferation of a significant population of undeleted hepatocytes.

The origin of the *Fxn^L2+^* hepatocytes is unknown. One hypothesis is that they might have been selected at an early age of the *Alb-Cre-Fxn^L3/L−^* mice because *Fxn^L2+^* hepatocytes are more resistant to Cre-mediated recombination than *Fxn^L3^* hepatocytes (H.P. and L.R., unpublished data), although no signal corresponding to the *Fxn^L2+^* allele could be observed by genotyping liver samples at 4 weeks. On the other hand, it has been recently reported that liver regeneration in mice could occur from albumin (Alb)-naive, and thus Cre-naive in our case, cells that progressively differentiate into hepatocytes and other hepatic cells after hepatectomy ([@b17-0050860]). In this case, *Fxn^L2+^* hepatocytes could have been selected after regeneration started, during the progressive differentiation of Alb-naive cells and expression of the Cre recombinase ([supplementary material Fig. S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009829/-/DC1)).

Interestingly, liver regeneration has previously been reported to occur in another conditional mouse model in which the *Alb-Cre* transgene was used to delete the *Cox10* gene ([@b11-0050860]). In this model, undeleted hepatocytes progressively replaced *Cox10*-deleted hepatocytes that were undergoing apoptosis ([@b11-0050860]), thus indicating that the *Alb-Cre* system is not fully efficient. This inefficiency, which was reported to result from defective Cre recombinase expression in a subset of hepatocytes ([@b11-0050860]), might thus participate in providing a pool of undeleted cells for the liver regeneration observed in *Alb-Cre-Fxn^L3/L−^* mice. However, no formation of lobules on the surface of the *Cox10*-deficient liver has been reported ([@b11-0050860]), suggesting that another phenomenon is taking place in *Alb-Cre-Fxn^L3/L−^* mice.

As indicated above, the lobules we observed in *Alb-Cre-Fxn^L3/L−^* mice contained large hepatocytes displaying key features of frataxin-deficient cells. These cells could account for the proportion of deleted cells in livers of surviving *Alb-Cre-Fxn^L3/L−^* mice, as observed by determination of the copy number of *Fxn^L−^* allele per genome. The deleted hepatocytes in the periphery of the liver might result from maintained expression of Cre recombinase in *Fxn^L2+^* hepatocytes, which would finally trigger deletion of exon 4. Furthermore, cell death was observed within the lobules, indicating that *Fxn*-deleted hepatocytes are not viable. The absence of a positive signal for KI67 in these large cells further indicated their incapacity to proliferate. Together, these data show that these structures are incompatible with tumor formation. In addition, tumor formation from *Fxn*-deleted cells is unlikely because previous data demonstrated that complete deletion of *Fxn* is not compatible with cellular proliferation ([@b5-0050860]).

Together, our data provide clear evidence that the development of lobules in *Alb-Cre-Fxn^L3/L−^* mice is associated with artifactual liver regeneration, inherent to the *Alb-Cre*-based mouse model, and that this phenotype cannot be directly attributed to frataxin deficiency in liver. We showed that *Fxn* deletion in liver triggers early mitochondriopathy, Fe-S cluster deficiency and liver failure, which lead to death in the majority of mice. While ageing, liver regeneration can eventually take over in some *Alb-Cre-Fxn^L3/L−^* mice, thus rescuing the phenotype resulting from early *Fxn* deletion and allowing mice to survive. Therefore, data obtained with *Alb-Cre-Fxn^L3/L−^* mice should be taken with care if old mice have been used to characterize the consequences of frataxin deficiency, such as in the recently reported reversion of carbohydrate metabolism impairment observed between 5-week-old and 17-month-old *Alb-Cre-Fxn^L3/L−^* mice ([@b43-0050860]).

In conclusion, both clinical investigations and characterization of the liver conditional mouse model described herein provide evidence that previously reported data suggesting that FRDA and frataxin deficiency are associated with predisposition to cancer and tumorigenesis need to be reconsidered.

METHODS
=======

Retrospective clinical analysis
-------------------------------

We reviewed anonymized data collected by an ongoing natural history study of FRDA from ten centers in the USA and one in Australia (FA-COMS cohort). All protocols were approved by the CHOP IRB. The medical history of 578 patients was assessed for the type and number of neoplasms recorded since the study's inception. A total of 1694 visits were analyzed. For purpose of analysis, all cellular dysplasias were excluded. The age of neoplasm diagnosis was also noted.

Data were also obtained from a European natural history study of FRDA, which started in 2011, currently involving eight clinical centers in Austria, Belgium, France, Germany, Italy and Spain (EFACTS cohort). All protocols obtained ethics approval from the European Commission, which supports the project, and from local Ethics Committees. Written informed consent was required from each individual to be included in the study. A detailed medical history that includes any neoplasm ever diagnosed for the patient was obtained. So far, only baseline data are available. As for the FA-COMS study, all cellular dysplasias were excluded from the analysis and the age of neoplasm diagnosis was noted.

Mice
----

Mice with a specific deletion of the *Fxn* gene in liver (*Alb-Cre-Fxn^L3/L−^*) were generated as previously described ([@b41-0050860]). Mice were analyzed in 87.5% C57BL/6J and 12.5% 129/Sv mixed background. Genotyping of the mice was carried out as previously described ([@b31-0050860]). Mice were maintained in a temperature and humidity controlled animal facility, with a 12-hour light and dark cycle and free access to water and a standard rodent chow (D03, SAFE, Villemoisson-sur-Orge, France). Breeding and maintenance of mice were performed according to institutional guidelines. Animals were killed by CO~2~ inhalation and tissues were immediately collected, weighed and frozen in liquid nitrogen or processed for biochemical and histological analysis.

Histopathology, immunohistochemistry and electron microscopy
------------------------------------------------------------

Tissues were dissected, fixed overnight in formalin, dried in 70% ethanol, embedded in paraffin and sectioned (5 μm) on a microtome using standard techniques. Some sections were stained with H&E. Histochemical analyses using Oil Red staining and SDH staining were carried out on cryostat sections (10 μm) of unfixed liver as described ([@b31-0050860]).

Immunohistochemistry was carried out on paraffin-embedded sections. Sections were dewaxed and hydrated using successive bathing in Histosol (2× 3 minutes), ethanol (2× 3 minutes), 90% ethanol (3 minutes), 70% ethanol (3 minutes) and water (5 minutes). Sections were then submitted to microwave treatment (2× 2.5 minutes at 800 W) in 10 mM citrate buffer, pH 6.0. Samples were washed in 0.05% PBS-Tween (PBS-T) (3× 5 minutes) before the addition of saturation buffer (PBS-T + 5% normal goat serum, NGS) for 30 minutes. The anti-KI67 antibody (NCL-Ki67p, Novocastra Laboratories; 1:500 in PBS-T + 5% NGS) was applied overnight at 4°C. Sections were then washed with PBS-T (3× 5 minutes) and exposed to goat anti-rabbit antibody coupled to Alexa Fluor 488 (Molecular Probes; 1:1000 in PBS-T + 5% NGS) for 1 hour at room temperature. Sections were washed with PBS-T (3× 5 minutes) and slides were mounted using Poly-Mount (Polysciences, Warrington, PA) mounting medium.

For electron microscopy, dissected livers were fixed in a freshly made mixture of 2.5% paraformaldehyde and 2.5% glutaraldehyde in cacodylate buffer (0.1 M, pH 7.2), rinsed in cacodylate buffer, postfixed in 0.1 M cacodylate buffer + 1% osmium tetroxide for 1 hour at 4°C, dehydrated and embedded in Epon. Ultrathin sections were cut at 70 nm and contrasted with uranyl acetate and lead citrate and examined with a Morgagni 268D electron microscope.

Immunoblotting
--------------

Total liver extracts were prepared as previously described ([@b22-0050860]). Immunoblotting was carried out using specific antibodies against frataxin (R1270, IGBMC, Illkirch, France; 1:1000), GPAT (R2372, IGBMC; 1:2000), βTUB (2A2, IGBMC; 1:40,000) and GAPDH (MAB374, Chemicon International; 1:20,000). Horseradish peroxidase-coupled secondary antibodies were used at a dilution of 1:5000.

Quantitative real-time PCR
--------------------------

Total RNA extraction, reverse transcription and qRT-PCR were achieved as previously reported ([@b22-0050860]). The following primers were used: *Fxn* forward, 5′-ATGG-CGTGCTCACCATTAAG-3′ and reverse, 5′-GGCCAATG-AAGACAAGTCCA-3′; *Alb* forward, 5′-GACAAGG-AAAGCTGCCTGAC-3′ and reverse, 5′-TTCTGCA-AAGTCAGCATTGG-3′. *Hprt* was used as a housekeeping gene ([@b22-0050860]). Quantitative deletion of the *Fxn^L3^* allele on genomic DNA was performed using the primers previously described to amplify the deleted allele ([@b31-0050860]) and primers amplifying the *Pepck* gene (forward, 5′-TCAACACCGACCTCCCTTAC-3′ and reverse, 5′-CAT-TGTGCCGCTATCTCAAA-3′) as control. Results were analyzed using the ΔCt method.

Xanthine oxido-reductase in-gel activity
----------------------------------------

Livers were homogenized in extraction buffer (20 mM Tris-HCl, 250 mM saccharose, pH 7.2, 2 mM EDTA, 40 mM KCl and Roche Complete Protease Inhibitor Cocktail) using an Ultraturax homogenizer. The homogenate was then centrifuged at 15,000 ***g*** for 15 minutes at 4°C. Supernatant (60 μg) was loaded onto 8% polyacrylamide native gel. After migration using SDS-glycine buffer, the gel was incubated in 250 mM Tris-HCl, pH 8.5, for 10 minutes before incubation in the staining buffer (0.5 mg/ml hypoxanthine, 0.5 mg/ml thiazolyl blue tetrazolium bromide and 50 μg/ml phenazine methosulfate). The reaction was stopped before saturation of the signal by washing several times with water.

Stastistical analyses
---------------------

Differences between mean values were evaluated using the bilateral Student's *t*-test. *P*\<0.05 was considered significant.
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